Ajanta Pharma Ltd (AJANTPHARM)
₹2381.05
Ajanta Pharma Ltd share Performance
- ₹2,370₹2,401.85₹2381.05
0.46%
Low
Day's Volatility:1.34%
High
0.87%
- ₹1,261.35₹2,540₹2381.05
47.03%
Low
52 Weeks Volatility:53.70%
High
6.68%
| Returns % | |
| 1 Month Return | + 15.22 % |
| 3 Month Return | + 11.95 % |
| 1 Year Return | + 87.97 % |
| Market Stats | |
| Previous Close | ₹₹2,395.25 |
| Open | ₹₹2,401.80 |
| Volume | ₹1.10L |
| Upper Circuit | ₹- |
| Lower Circuit | ₹- |
| Market Cap | ₹₹30,160.19Cr |
Analyst Rating
based on 10 analysts
Based on 10 analysts offering long term price targets for Ajanta Pharma Ltd. An average target of ₹2440.1
Source: S&P Global Market Intelligence
Company Information
Share Price: ₹2381.05 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹30,160.19Cr as of today
Revenue: ₹1,054.08Cr as on March 2024 (Q1 24)
Net Profit: ₹202.72Cr as on March 2024 (Q1 24)
Listing date: 05 Jun, 2000
Chairperson Name: Mannalal B Agrawal
| Organisation | Ajanta Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Ajanta Pharma Ltd
Ajanta Pharma's Revenues Beat Analyst Predictions - 05 May, 2024
Ajanta Pharma's yearly results show revenues of ₹43b, beating analyst predictions by 2.2%. EPS came in at ₹64.77, 2% above expectations. The company's ten analysts forecast a 9.8% improvement in revenue to ₹47.1b and per-share earnings are expected to swell 14% to ₹74.00. Price target rose 6.8% to ₹2,425.
Ajanta Pharma Q4 Results Show YoY Growth in Revenue and Profit - 04 May, 2024
Ajanta Pharmaceuticals' Q4 results show a 19.53% YoY increase in revenue and a 65.82% YoY increase in profit. However, compared to the previous quarter, there was a decline in both revenue and profit. The consensus recommendation as of May 4th is to Buy.
Ajanta Pharma Reports Strong Q4 Results and Approves Share Buyback - 03 May, 2024
Ajanta Pharma reports strong Q4 results with a surge in net profit and revenue growth. The company also approves a share buyback of up to Rs.285 crore.
Ajanta Pharma Reports Strong Q4 Results and Approves Share Buyback - 02 May, 2024
Ajanta Pharma's consolidated net profit rose by 66% YoY to Rs 203 crore in the March quarter, with revenue from operations growing by 20%. The company approved a share buyback of up to Rs 285 crore, involving the purchase of 10,28,881 equity shares at a price of Rs 2,770 per share. Ajanta Pharma expects its overall FY25 revenue growth to be in the low teens.
Ajanta Pharma to Consider Equity Share Buy-Back Proposal - 01 May, 2024
Ajanta Pharma will be considering a proposal for buy-back of equity shares in accordance with applicable laws.
Ajanta Pharma Board Considers Buyback; ROE Higher Than Industry Average - 26 Apr, 2024
Ajanta Pharma's board will consider a fourth share buyback in four years and Q4 results on May 2, 2024. The company's ROE is higher than the industry average, with future payout ratio expected to rise. Following the buyback announcement, Ajanta Pharma stock surged 3.6% and turned positive for 2024.
Fundamentals of Ajanta Pharma Ltd
Insights on Ajanta Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 13.86% to 14.76% in Mar 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, AJANTPHARM stock has moved up by 15.2%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 66.21% of holdings in Mar 2024 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.6% return, outperforming this stock by 40.0%
- NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 94.5% return, outperforming this stock by 6.5%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 1.11K Cr → 1.08K Cr (in ₹), with an average decrease of 2.6% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.01% to 7.76% in Mar 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 210.03 Cr → 202.72 Cr (in ₹), with an average decrease of 3.5% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 9.11% to 8.54% in Mar 2024 quarter
Ajanta Pharma Ltd Valuation
Ajanta Pharma Ltd in the last 5 years
Lowest (17.12x)
June 6, 2018
Today (36.95x)
May 16, 2024
Industry (61.87x)
May 16, 2024
Highest (40.01x)
December 29, 2023
Shareholding Pattern
| Investors | Holdings % | Prev. 1 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 66.21% | 0.00 | |
| Foreign Institutions | 8.54% | 0.00 | |
| Mutual Funds | 14.76% | 0.00 | |
| Retail Investors | 7.76% | 0.00 | |
| Others | 2.73% | 0.00 |
Technicals of Ajanta Pharma Ltd share
News & Events of Ajanta Pharma Ltd
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Ajanta Pharma Ltd shares.
Ajanta Pharma Ltd (AJANTPHARM) share price today is ₹2381.05
Ajanta Pharma Ltd is listed on NSE
Ajanta Pharma Ltd is listed on BSE
- Today’s highest price of Ajanta Pharma Ltd is ₹2401.85.
- Today’s lowest price of Ajanta Pharma Ltd is ₹2370.
PE Ratio of Ajanta Pharma Ltd is 36.95
PE ratio = Ajanta Pharma Ltd Market price per share / Ajanta Pharma Ltd Earnings per share
Today’s traded volume of Ajanta Pharma Ltd(AJANTPHARM) is 1.10L.
Today’s market capitalisation of Ajanta Pharma Ltd(AJANTPHARM) is ₹30160.19Cr.
| Ajanta Pharma Ltd(AJANTPHARM | Price |
|---|---|
52 Week High | ₹2540 |
52 Week Low | ₹1261.35 |
Ajanta Pharma Ltd(AJANTPHARM) share price is ₹2381.05. It is down -6.26% from its 52 Week High price of ₹2540
Ajanta Pharma Ltd(AJANTPHARM) share price is ₹2381.05. It is up 88.77% from its 52 Week Low price of ₹1261.35
| Ajanta Pharma Ltd(AJANTPHARM | Returns |
|---|---|
1 Day Returns | -14.2% |
1 Month Returns | 15.22% |
3 Month Returns | 11.95% |
1 Year Returns | 87.97% |